{"id":"W4365512278","doi":"10.1158/1538-7445.am2023-ct202","title":"Abstract CT202: Xevinapant plus avelumab in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Phase 1b dose-expansion results and exploratory biomarker analyses","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University; Ottawa Hospital; Spinal Cord Injury BC; University of British Columbia; University of Alberta","funders":"","keywords":"Medicine; Internal medicine; Avelumab; Response Evaluation Criteria in Solid Tumors; Oncology; Lung cancer; Clinical endpoint; Progressive disease; Adverse effect; Cohort; Cancer; Chemotherapy; Tolerability; Gastroenterology; Immunotherapy; Nivolumab; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001448932,0.0009044912,0.001210746,0.0002926764,0.0002611156,0.0006465208,0.0005546165,0.000548283,0.00238737],"category_scores_gemma":[0.0007337857,0.0003411644,0.0008606304,0.0003793459,0.0004995075,0.0006040562,0.00030195,0.001905235,0.0005786424],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009743065,"about_ca_system_score_gemma":0.0011987,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008175841,"about_ca_topic_score_gemma":0.002159578,"domain_scores_codex":[0.9995167,0.0002666857,0.00002249259,0.00007787778,0.00006156845,0.00005460855],"domain_scores_gemma":[0.9995308,0.00008456912,0.00009756764,0.00004393472,0.00004140749,0.0002017046],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5768759,0.05928129,0.03426117,0.0007561201,0.001965134,0.0003765299,0.0003172502,0.005202026,0.1534589,0.0001922268,0.005518346,0.1617951],"study_design_scores_gemma":[0.1889545,0.7188782,0.06201804,0.00004164,0.0009146075,0.0007508293,0.00007064961,0.002596455,0.02092441,0.0001648305,0.004640682,0.00004521083],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9962181,0.001022917,0.0003066952,0.0001741571,0.00002578202,0.0006728847,0.0007418589,0.00004569063,0.0007919065],"genre_scores_gemma":[0.9934143,0.0007209518,0.001194811,0.0002836098,0.00006677128,0.0006490232,0.002283246,0.00001909497,0.001368248],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00238737,"threshold_uncertainty_score":0.007986546,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1420479036548676,"score_gpt":0.4893348605240234,"score_spread":0.3472869568691557,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}